scholarly journals The Potential Use of Radiomics with Pre-Radiation Therapy MR Imaging in Predicting Risk of Pseudoprogression in Glioblastoma Patients

2021 ◽  
Vol 7 (2) ◽  
pp. 17
Author(s):  
Michael Baine ◽  
Justin Burr ◽  
Qian Du ◽  
Chi Zhang ◽  
Xiaoying Liang ◽  
...  
Keyword(s):  
Clinical Features ◽  
Dna Methyltransferase ◽  
Predictive Ability ◽  
Post Treatment ◽  
Model Combination ◽  
Methylguanine Dna Methyltransferase ◽  
Mri Scans ◽  
Area Under Roc Curve ◽  
True Progression ◽  
Potential Use

Glioblastoma (GBM) is the most common adult glioma. Differentiating post-treatment effects such as pseudoprogression from true progression is paramount for treatment. Radiomics has been shown to predict overall survival and MGMT (methylguanine-DNA methyltransferase) promoter status in those with GBM. A potential application of radiomics is predicting pseudoprogression on pre-radiotherapy (RT) scans for patients with GBM. A retrospective review was performed with radiomic data analyzed using pre-RT MRI scans. Pseudoprogression was defined as post-treatment findings on imaging that resolved with steroids or spontaneously on subsequent imaging. Of the 72 patients identified for the study, 35 were able to be assessed for pseudoprogression, and 8 (22.9%) had pseudoprogression. A total of 841 radiomic features were examined along with clinical features. Receiver operating characteristic (ROC) analyses were performed to determine the AUC (area under ROC curve) of models of clinical features, radiomic features, and combining clinical and radiomic features. Two radiomic features were identified to be the optimal model combination. The ROC analysis found that the predictive ability of this combination was higher than using clinical features alone (mean AUC: 0.82 vs. 0.62). Additionally, combining the radiomic features with clinical factors did not improve predictive ability. Our results indicate that radiomics is potentially capable of predicting future development of pseudoprogression in patients with GBM using pre-RT MRIs.

scholarly journals Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Ling-Wei Kong ◽  
Jin Chen ◽  
Heng Zhao ◽  
Kun Yao ◽  
Sheng-Yu Fang ◽  
...  
Keyword(s):  
Molecular Markers ◽  
Dna Methyltransferase ◽  
Area Under The Curve ◽  
Predictive Ability ◽  
Low Grade ◽  
Isocitrate Dehydrogenase 1 ◽  
Methylguanine Dna Methyltransferase ◽  
Non Invasive ◽  
Marker Status ◽  
The Relationship

AbstractSusceptibility-weighted imaging (SWI) can be a useful tool to depict vascular structures in brain tumors as well as micro-bleedings, which represent tumor invasion to blood vessels and could also be representative of tumoral angiogenesis. In this study, we investigated the relationship between SWI features and glioma grades, and the expression of key molecular markers isocitrate dehydrogenase 1 (IDH1), O-6-methylguanine-DNA methyltransferase (MGMT), and 1p19q. The gliomas were graded according to the intratumoral susceptibility signals (ITSS). We used the Mann-Whitney test to analyze the relationship between ITSS grades and the pathological level and status of these markers. Additionally, the area under the curve (AUC) was used to determine the predictive value of glioma SWI characteristics for the molecular marker status. In these cases, the ITSS grades of low-grade gliomas (LGG) were significantly lower than those of high-grade gliomas (HGG). Similarly, the ITSS grades of gliomas with IDH1 mutations and MGMT methylation were significantly lower than those of gliomas with Wild-type IDH1 and unmethylated MGMT. However, ITSS grades showed no relationship with 1p19q deletion status, while they did show significant predictive ability for glioma grade, IDH1 mutation, and MGMT methylation. These findings indicate an association between some molecular markers and cerebral microbleeds in gliomas, providing a new avenue for non-invasive prediction of molecular genetics in gliomas and an important basis for preoperative personalized surgical treatment based on molecular pathology.

Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers

2016 ◽  
Vol 16 (6) ◽  
pp. 455-464 ◽  
Author(s):  
Kalkunte S. Srivenugopal ◽  
Amit Rawat ◽  
Suryakant K. Niture ◽  
Ameya Paranjpe ◽  
Chinavenmani Velu ◽  
...  
Keyword(s):  
Dna Methyltransferase ◽  
Posttranslational Regulation ◽  
Methylguanine Dna Methyltransferase

Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability

2016 ◽  
Vol 13 (1) ◽  
pp. 28-39 ◽  
Author(s):  
Patrick-Denis St-Coeur ◽  
Marc Cormier ◽  
Veronique LeBlanc ◽  
Pier Morin ◽  
Mohamed Touaibia
Keyword(s):  
Dna Methyltransferase ◽  
Glioblastoma Cells ◽  
Methylguanine Dna Methyltransferase

scholarly journals Purification, structure, and biochemical properties of human O6-methylguanine-DNA methyltransferase.

1990 ◽  
Vol 265 (25) ◽  
pp. 14754-14762
Author(s):  
G. Koike ◽  
H. Maki ◽  
H. Takeya ◽  
H. Hayakawa ◽  
M. Sekiguchi
Keyword(s):  
Dna Methyltransferase ◽  
Biochemical Properties ◽  
Methylguanine Dna Methyltransferase

scholarly journals Molecular and Circulating Biomarkers of Brain Tumors

2021 ◽  
Vol 22 (13) ◽  
pp. 7039
Author(s):  
Wojciech Jelski ◽  
Barbara Mroczko
Keyword(s):  
Brain Tumors ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Extracellular Vesicles ◽  
Dna Methyltransferase ◽  
Growth Factor Receptor ◽  
Response To Treatment ◽  
Liquid Biopsies ◽  
Methylguanine Dna Methyltransferase ◽  
The Central Nervous System

Brain tumors are the most common malignant primary intracranial tumors of the central nervous system. They are often recognized too late for successful therapy. Minimally invasive methods are needed to establish a diagnosis or monitor the response to treatment of CNS tumors. Brain tumors release molecular information into the circulation. Liquid biopsies collect and analyze tumor components in body fluids, and there is an increasing interest in the investigation of liquid biopsies as a substitute for tumor tissue. Tumor-derived biomarkers include nucleic acids, proteins, and tumor-derived extracellular vesicles that accumulate in blood or cerebrospinal fluid. In recent years, circulating tumor cells have also been identified in the blood of glioblastoma patients. In this review of the literature, the authors highlight the significance, regulation, and prevalence of molecular biomarkers such as O6-methylguanine-DNA methyltransferase, epidermal growth factor receptor, and isocitrate dehydrogenase. Herein, we critically review the available literature on plasma circulating tumor cells (CTCs), cell-free tumors (ctDNAs), circulating cell-free microRNAs (cfmiRNAs), and circulating extracellular vesicles (EVs) for the diagnosis and monitoring of brain tumor. Currently available markers have significant limitations.While much research has been conductedon these markers, there is still a significant amount that we do not yet understand, which may account for some conflicting reports in the literature.

Sign in / Sign up

Export Citation Format

Share Document